Clinical Trial Search

Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Acyclovir as…

Primary: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.64; -1.59; -1.41 percentage of glycosylated hemoglobin — p=<0.001

Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 of Each Treatment Period — 6.030; 4.189; 4.500…

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Ortho-Cyclen - Norelgestromin (NGMN) — 17900; 16000 picograms*hour/milliliter…

Primary: Progression-Free Survival (PFS) — 6.4; 6.7 months — p=0.886

Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Score); Change From Baseline at 4 Months — 27.1; 33.3; 28.9; 26.7 units on a scale

Primary: Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score — 93.4; 92.1; 55.0; 63.4 Scores on a scale

Primary: Number of Participants Who Fell on a Tripping Test — 2; 4 participants — p=0.45

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: AHI on Nasal Mask and Pillows Mask — 1.7; 1.9 events/hour

Primary: Total Unprotected Anal Intercourse Events (Exclusive of Those Events With a Primary HIV-negative Partner) — 4.23; 3.91; 3.41; 2.05 Self reported events in past 3 months

Primary: Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV) — 10256; 23150 nanograms*hour/milliliter/milligram

Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin — 3210; 3240; 2970 nanograms times hour/milliliter(ng*h/mL)

Primary: Overall Survival (OS) — 18.3; 16.7 months of survival

Primary: Which One Product That Relieves Nasal Congestion do You Buy Most Often? — 46; 29; 6; 3 Participants